ImmunAbs

ImmunAbs Inc. is a South Korean biopharmaceutical company established in 2017 by experts with global antibody therapeutics development experience, operating under the vision 'Hope for Patients, Dreams for All.' The company develops antibody therapeutics for rare and underserved conditions including autoimmune diseases, diabetic retinopathy, and diabetes, leveraging technologies such as phage display and single B cell cloning. Its lead pipeline candidate IM-101 targets autoimmune diseases where complement system defects destroy red blood cells, aiming to provide a more effective and affordable alternative to existing high-cost treatments. ImmunAbs is headquartered in Songpa-gu, Seoul, with an R&D center co-located in the same district.